IDBS Expands in Asia Pacific
News Nov 10, 2009
IDBS has announced that it has expanded its Asia Pacific presence with new centers in both China and Australia.
From these new offices IDBS is now providing customers with direct local support and training, as well as sales and business development across the entire portfolio of IDBS products; ActivityBase, E-WorkBook and InforSense Suites.
IDBS now has the largest presence in China of any life sciences software company.
IDBS’ organization in China is being run from Shanghai by David Hadfield and serves customers in mainland China, Hong Kong and Taiwan. Mr. Hadfield was formerly Senior Vice President and general manager at Spotfire and previously held senior executive roles at Molecular Devices Inc., and Oxford GlycoSciences, as well as senior management positions at Applied Biosystems.
IDBS has also expanded its existing Australian operations under the leadership of Conor Higgins. This organisation will serve customers in Australia, New Zealand and South East Asia. Mr Higgins, who has already developed a strong IDBS user base in Australia, has over 15 years experience in the IT field specializing in data security, compliance and management. He has previously helped organizations such as Watchfire (IBM), Ironport (CSICO), and Acopia (F5Networks) expand their businesses in the region.
“IDBS is well known for developing close, constructive relationships with our customers. We are extremely pleased to be able to make this major commitment to the region and serve our expanding customer base with the highest level of dedicated, culturally aware, support and training. Our proven Translational Research offerings also have a significant role to play in this expansion.” said Neil Kipling, founder and CEO of IDBS.
Chris Molloy, VP Corporate Development and APAC added: “We are delighted to have two such experienced and dedicated leaders in place as we continue our regional development. This investment reflects the rapid growth of the R&D market in Asia Pacific and the ‘must-have’ requirement for robust enterprise data management solutions which we already provide in the region and worldwide.”
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
BOC Sciences Continues to Enlarge Its Publication Collection Using BOC Sciences ProductsNews
BOC Sciences continues to add more publication items that used BOC Sciences products in their researches to its already existing collection.READ MORE